Immunogenicity and Safety of a Tetravalent Dengue Vaccine Given as a Booster Injection in Adolescents and Adults Who Previously Completed the 3-dose Schedule in a Study Conducted in Latin America

Trial Profile

Immunogenicity and Safety of a Tetravalent Dengue Vaccine Given as a Booster Injection in Adolescents and Adults Who Previously Completed the 3-dose Schedule in a Study Conducted in Latin America

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 22 Nov 2017

At a glance

  • Drugs CYD TDV (Primary)
  • Indications Dengue
  • Focus Adverse reactions
  • Sponsors sanofi pasteur
  • Most Recent Events

    • 28 Jun 2017 Planned End Date changed from 1 Aug 2019 to 2 Jan 2019.
    • 25 Oct 2016 Status changed from recruiting to active, no longer recruiting.
    • 15 Apr 2016 Planned End Date changed from 1 Jan 2019 to 1 Aug 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top